Is Nationalism Transforming the Pharma Manufacturing Map?

The last few years have seen a rise in nationalism and populism across the world. In 2016, the US voted in the populist Donald Trump on his promise to ‘Make America Great Again’. In 2018, Hungary re-elected its national conservative prime minister Viktor Orbán with the slogan ‘ For us, Hungary is first’. And in 2019, India re-elected its Hindu nationalist ruler, Nehendra Modi, and the UK elected (with a large majority) the Eurosceptic Boris Johnson on his pledge to ‘Get Brexit Done’.

Data Room Structure Guideline

At PharmaVentures, a data room is used as a location to store essential documents that are needed during an M&A or Divestment transaction. It is an essential part of the due diligence process which interested buyers access prior to closing a transaction.

The evolving therapeutic landscape in haematologic malignancies

Haematological malignancies are types of cancers affecting blood, bone marrow and lymph nodes. Broadly speaking, there are three major types of blood cancers: leukaemia, lymphoma and myeloma. Of these, the most common blood cancer types include non-Hodgkin lymphoma (NHL), chronic lymphocytic leukaemia (CLL), acute myeloid leukaemia (AML) and multiple myeloma (MM).

M&A in COVID-19 environment and beyond Keep your perspective

As you are aware PharmaVentures is a sector focused advisory firm and we are at the forefront of deal-making activity in the pharmaceutical, biotech, medtech and service sector industries such as CROs and CDMOs. Given the current backdrop and challenges facing companies executing live transactions or contemplating entering acquisition or divestment processes, we thought it may be useful to share with you our thoughts on the current deal-making environment and what we see in the 'trenches' of ongoing processes for our clients. 

Dancing with the Dragon Cross-border Transactions between China and the World

There is strong appetite for cross-border transactions between China and the rest of the world. Improved overall market environment will encourage attractive deal terms and future market potential. Selecting the right partner and effective communication are key for a successful long-term relationship.

Valuation Series: How to Interpret and Negotiate Deal Terms for a Life Science Licensing Agreement

This is the first in a series of white papers by the experts at PharmaVentures that explores the challenges of valuing drug candidates at various stages of clinical development. This series is based on the experiences we have encountered using valuation in actual negotiations with the various pitfalls that negotiators and valuation practitioners have while negotiating a deal.

Are Diagnostics Poised to Lead Healthcare Or Is This Another False Positive?

Even though medical diagnosis can be traced back to ancient Egypt in the 26th century BC (Edwin Smith Papyrus by Imhotep), in vitro diagnostics (IVD) as a field really started to take shape from late 20th century. Significant investments and research have been funnelled into early diagnosis of cancer with new products including next-generation sequencing, liquid biopsy and companion diagnostics, whilst payers are increasingly demanding biomarker stratification to justify the use of expensive drugs.

The Rise of Gene Therapies in Neurological Diseases

In the recent years, the level of interest in Gene Therapy from both industry and academia has been unparalleled. CNS disorders in particular have gained a lot of attention with a considerable emphasis on neurological targets; and this is especially visible when analysing several high-profile deals that occurred in 2018. The biggest stand-out deal was struck by Novartis, buying AveXis for $8.7 billion giving the Basel based biopharma company access to what could potentially be the first one-time only treatment for Spinal Muscular Atrophy (SMA).

Immuno-Oncology Drives Better Outcomes In NSCLC, But Is This Now An Overcrowded Space?

Barely a month passes without an announcement of improved survival rates for non-small cell lung cancer (NSCLC) patients. Much of this has been driven by favouring a personalised medicine approach over the historic “one size fits all” chemotherapy paradigm. Drugs which target specific mutations such as EGFR and ALK have been at the forefront and this has been further supplemented with the application of anti-PD-1/PD-L1 agents (as monotherapies or in combination) where Merck’s Keytruda® (Pembrolizumab) has been leading the charge.

China Healthcare 2.0 - Age of Consolidation, Innovation and Capital Deployment

Despite the impressive growth observed in China over the last two decades and with a projected healthcare market of RMB 8 trillion (USD 1.2 trillion), Chinese life science companies lag behind toptiered Western counterparts, both in terms of market capitalisation and innovation. What makes 2017 remarkable is that the age of pure window shopping by Chinese players seems to be something of the past and companies are actively pursuing international strategies. Ambitious and visionary pharmaceutical companies and healthcare investors are all establishing their footprints across the world.

Pages